Thomas Powles
MD, MBBS
Professor of GU Oncology and Director of Barts Cancer Centre
👥Biography 个人简介
Dr. Thomas Powles is a global leader in urothelial and renal cell carcinoma and was a principal investigator in the EV-302 trial that established enfortumab vedotin plus pembrolizumab as the preferred first-line treatment for cisplatin-ineligible metastatic urothelial carcinoma. His work has shaped urothelial cancer treatment paradigms across multiple lines of therapy. He is a central figure in international bladder and kidney cancer research.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Thomas Powles 的研究动态
Follow Thomas Powles's research updates
留下邮箱，当我们发布与 Thomas Powles（Queen Mary University of London / Barts Cancer Centre）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment